The Lynx Group
Cholangiocarcinoma News

Web Exclusives

Web Exclusives — March 22, 2022
The current standard first-line therapy for advanced cholangiocarcinoma (CCA) is the chemotherapy combination of gemcitabine plus cisplatin; only about 40% of patients are amenable to surgery.
Read More

Web Exclusives — December 20, 2021
Infigratinib demonstrates significant efficacy and a manageable safety profile in patients with previously treated, locally advanced or metastatic CCA with an FGFR2 gene fusion or rearrangement.
Read More

Web Exclusives — December 20, 2021
The ClarIDHy trial demonstrated safety and efficacy of ivosidenib in patients with previously treated metastatic CCA harboring an IDH1 mutation.
Read More

Web Exclusives — December 20, 2021
Initial results of the phase 2 FOENIX-CCA2 study demonstrated that futibatinib demonstrated efficacy and a manageable safety profile in patients with previously treated iCCA harboring an FGFR2 fusion or rearrangement.
Read More

Web Exclusives — December 20, 2021
The phase 2 FIDES-01 study demonstrated that derazantinib resulted in objective responses and a manageable safety profile in patients with previously treated iCCA with an FGFR2 fusion or rearrangement.
Read More

Web Exclusives — December 20, 2021
Results from a phase 1 study showed that the bispecific HER2-targeted antibody zanidatamab is well-tolerated and demonstrates clinical activity in patients with HER2-overexpressing biliary tract cancer.
Read More

Web Exclusives — December 20, 2021
The NIFE study demonstrated the efficacy and safety of the nal-IRI-plus-5-FU/LV regimen as first-line therapy in patients with advanced biliary tract cancer, with a clear benefit over gemcitabine/cisplatin in extrahepatic cholangiocarcinoma.
Read More

Web Exclusives — November 9, 2021
On November 3, 2021, TransThera Sciences announced that the FDA granted its investigational drug, TT-00420, a spectrum-selective multi-kinase inhibitor, a fast-track designation for the treatment of patients with cholangiocarcinoma (CCA) who have no available standard treatment options. In preclinical studies, TT-00420 has shown high activity in a variety of FGFR mutations.
Read More

Web Exclusives — October 28, 2021
On October 25, 2021, AstraZeneca announced high-level positive results from the phase 3 clinical trial TOPAZ-1, demonstrating that adding the immunotherapy durvalumab (Imfinzi) to first-line standard-of-care chemotherapy leads to a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone in patients with advanced biliary tract cancer.
Read More

Web Exclusives — August 30, 2021
Ivosidenib has been approved by the FDA for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
Read More

Page 1 of 3

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: